Intest Res.  2016 Jan;14(1):15-20. 10.5217/ir.2016.14.1.15.

Current status of biosimilars in the treatment of inflammatory bowel diseases

• Park DI

• KMID: 2174505
• DOI: http://doi.org/10.5217/ir.2016.14.1.15

Abstract

Introduction
of biological therapies have led to dramatic changes in the management of debilitating immune-mediated inflammatory bowel diseases (IBD) including ulcerative colitis and Crohn's disease. However, the long term use of these agents may be very expensive, placing a significant burden on National Healthcare Systems. The development of first biosimilar to infliximab, CT-P13 (Remsima; Celltrion Inc., Incheon, Korea and Inflextra; Hospiral, Lake Forest, Illinois, USA) has become another way to decrease the medical care cost and increase patient treatment option, but, actual equivalence of efficacy and safety of CT-P13 was investigated in rheumatic diseases only. The extrapolation of outcome from rheumatic trials to IBD and the interchangeability of CT-P13 with infliximab have come to be a matter of concern. Two recent retrospective studies reported the similarity of CT-P13 in terms of efficacy and safety. Infliximab biosimilars may be promising new treatment options for IBD patients, however, well-designed, prospective randomized non-inferiority trials should be needed to confidently integrate infliximab biosimilars into IBD treatment.

Keyword

Inflammatory bowel diseases; Biosimilar; Pharmacy; CT-P13

MeSH Terms

Biological Therapy
Colitis, Ulcerative
Crohn Disease
Delivery of Health Care
Health Care Costs
Humans
Illinois
Incheon
Infliximab
Inflammatory Bowel Diseases*
Korea
Lakes
Pharmacy
Prospective Studies
Retrospective Studies
Rheumatic Diseases
Trees

Reference

1. Wiens A, Venson R, Correr CJ, Otuki MF, Pontarolo R. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy. 2010; 30:339–353. PMID: 20334454.

2. Bansback N, Sizto S, Sun H, Feldman S, Willian MK, Anis A. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology. 2009; 219:209–218. PMID: 19657180.

3. Billiet T, Rutgeerts P, Ferrante M, Van Assche G, Vermeire S. Targeting TNF-α for the treatment of inflammatory bowel disease. Expert Opin Biol Ther. 2014; 14:75–101. PMID: 24206084.

4. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut. 2009; 58:492–500. PMID: 18832518.

5. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012; 142:46–54. PMID: 22001864.

6. Hu PJ. Inflammatory bowel disease in Asia: the challenges and opportunities. Intest Res. 2015; 13:188–190. PMID: 26130991.

7. Liu Y, Wu EQ, Bensimon AG, et al. Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis. Adv Ther. 2012; 29:620–634. PMID: 22843208.

8. US Food and Drug Administration. Guidance for industry: quality considerations in demonstrating biosimilarity to a reference protein product. Accessed May 21, 2014. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.pdf. Published 2012.

9. Gecse KB, Khanna R, van den, et al. Biosimilars in IBD: hope or expectation? Gut. 2013; 62:803–807. PMID: 23503043.

10. European Medicines Agency. Procedural advice for users of the centralized procedure for similar biological medicinal products applications. London, UK: European Medicines Agency;2011. EMA/940451/2011.

11. US Government. Title VII - Improving access to innovative medical therapies: Subtitle A - Biologics price competition and innovation. H.R. 3590 - Patient protection and affordable care act. 111th Cong;2009-2010:686-703. Accessed November 20, 2013. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/UCM216146.pdf.

12. Merck. 2013 Merck Annual Report. Accessed March 5, 2014. http://www.merck.com/investors/financials/annual-reports/.

13. Beck A, Sanglier-Cianférani S, Van Dorsselaer A. Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry. Anal Chem. 2012; 84:4637–4646. PMID: 22510259.

14. Schellekens H. Immunologic mechanisms of EPO-associated pure red cell aplasia. Best Pract Res Clin Haematol. 2005; 18:473–480. PMID: 15792922.

15. Jelkmann W. Biosimilar epoetins and other "follow-on" biologics: update on the European experiences. Am J Hematol. 2010; 85:771–780. PMID: 20706990.

16. Dörner T, Strand V, Castañeda-Hernández G, et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis. 2013; 72:322–328. PMID: 23253920.

17. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013; 72:1613–1620. PMID: 23687260.

18. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013; 72:1605–1612. PMID: 23687259.

19. Summary basis of decision (SBD) for Remsima. Health Canada Web site. Accessed April 9, 2014. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbdsmd/drug-med/sbd_smd_2014_remsima_160195-eng.php. Published April 1, 2014.

20. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Assessment report: inflectra. Accessed December 2, 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002778/WC500151490.pdf. Published June 27, 2013.

21. Lee H. Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars? AAPS J. 2014; 16:22–26. PMID: 24114449.

22. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003; 348:601–608. PMID: 12584368.

23. Flood J. Tumor necrosis factor inhibitors in the treatment of chronic inflammatory diseases. A review of immunogenicity and potential implications. Manag Care. 2009; 18(4 Suppl 3):1–5. PMID: 19562866.

24. American Academy of Dermatology and AAD Association. Position statement on generic therapeutic & biosimilar substitution. Last amended August 3, 2013. Accessed May 9, 2014. http://www.aad.org/Forms/Policies/Uploads/PS/PSGeneric%20Therapeutic%20and%20%20Biosimilar%20Substitution.pdf. Published March 29, 2013.

25. Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R. Epoetin Zeta Study Group. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Curr Med Res Opin. 2008; 24:625–637. PMID: 18208642.

26. McCamish M, Woollett G. The continuum of comparability extends to biosimilarity: how much is enough and what clinical data are necessary? Clin Pharmacol Ther. 2013; 93:315–317. PMID: 23443756.

27. Jung YS, Park DI, Kim YH, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol. 2015; 30:1705–1712. PMID: 25974251.

28. Park SH, Kim YH, Lee JH, et al. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Rev Gastroenterol Hepatol. 2015; 9(Suppl 1):35–44. PMID: 26395533.

29. Ben-Horin S, Yavzori M, Benhar I, et al. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima. Gut. [published online ahead of print April 20, 2015]. DOI: 10.1136/gutjnl-2015-309290.